Melbourne, Australia, 07 January 2020: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, are pleased to announce the attendance of the senior management team including Chief Executive Officer, Professor Darren Kelly at the 38th J.P. Morgan Healthcare Conference.
The conference will be held between 13th – 16th January 2020 in San Francisco, California. The OccuRx team will attend following continued discussions with J.P. Morgan and other biotechnology investment firms. The OccuRx team will highlight their scientific advancements in anti-inflammatory and anti-fibrotic therapies, including their clinical development progress and plans with its novel therapeutic platform for the treatment of fibrotic diseases (including diabetic kidney disease, diabetic retinopathy, wet age-related macular degeneration (AMD) and chronic kidney disease).
OccuRx is dedicated to identifying and validating novel targets that treat and prevent fibrosis that lead to disease progression and end organ failure. The company’s most advanced molecule drug candidate, OCX063, is being developed as a first-in-class oral therapy for the treatment for both kidney and ocular diseases. OCX063, is a small molecule drug with the potential to prevent the growth of new and abnormal blood vessels and reduce inflammation.
Diabetes continues to be a major public health problem and has many serious complications that affect multiple organs of the body particularly the eye, kidneys and blood vessels. Over time damage to blood vessels of the eyes and filtering units in the kidneys occurs, leading to chronic inflammation, microvascular changes and irreversible fibrosis. Ultimately this can result in both diabetic kidney and eye disease, both of which are associated with significant morbidity and/or mortality including end stage kidney disease and, in the eye, diabetic retinopathy and blindness. With no cure available, intensive research is required to develop novel treatment possibilities.
There are currently no treatments available for kidney fibrosis, which presents in the majority of patients with chronic kidney disease (CKD). Given the enormous cost of dialysis and kidney transplants to the healthcare system, finding an effective treatment for these patients remains one of the global healthcare industry’s largest unmet needs. OccuRx is using genetic analysis to identify the most suitable patients for treatment.
The J.P. Morgan Healthcare Conference is the largest healthcare investment conference in the United States. It brings together industry leaders, investors, fast-growth companies, and emerging technology creators in healthcare.